论文部分内容阅读
目的探讨颞浅动脉旁注射吡哆胺在改善糖尿病视网膜病变患者症状、延缓糖尿病视网膜病变进展中的作用。方法糖尿病视网膜病患者60例(120眼)随机分为治疗组和对照组各30例(60眼),治疗组口服复方血栓通,并给予颞浅动脉旁注射吡哆胺2mL/次,1次/周,共6个月;对照组仅口服复方血栓通治疗。比较2组治疗前、后前房水终末糖基化产物(advanced glycation end products,AGEs)浓度及视网膜病变程度。结果治疗组治疗后前房水AGEs水平((0.12±0.09)μg/L)低于治疗前((0.26±0.06)μg/L)(P<0.05),对照组治疗后前房水AGEs水平((0.28±0.04)μg/L)高于治疗前((0.24±0.07)μg/L)(P<0.05),2组治疗后AGEs比较差异有统计学意义(P<0.05);注射后治疗组未发生不良反应,前房水内吡哆胺水平高于对照组(P<0.05)。结论颞浅动脉旁局部注射吡哆胺可降低眼内AGEs浓度,延缓糖尿病视网膜病情进展。
Objective To investigate the effect of injection of pyridoxamine beside the superficial temporal artery on the improvement of the symptoms and the progression of diabetic retinopathy in patients with diabetic retinopathy. Methods Sixty diabetic retinopathy patients (120 eyes) were randomly divided into treatment group (30 eyes) and control group (30 eyes). The treatment group was given compound Xueshuantong and the rats were injected with pyridoxamine 2mL / / Week, a total of 6 months; control group only oral compound Xueshuantong treatment. The levels of advanced glycation end products (AGEs) and retinopathy were compared between the two groups before and after treatment. Results The level of AGEs in the aqueous humor of the control group was significantly lower than that before treatment (0.12 ± 0.09 μg / L, 0.26 ± 0.06 μg / L, P <0.05) (0.28 ± 0.04) μg / L) was higher than that before treatment (0.24 ± 0.07 μg / L) (P <0.05). There was significant difference in AGEs between the two groups after treatment (P <0.05) No side effects occurred, and the level of pyridoxamine in aqueous humor was higher than that of the control group (P <0.05). Conclusions Local injection of pyridoxamine into the superficial temporal artery can decrease the intraocular AGEs concentration and delay the progression of diabetic retinopathy.